

Kappaproct[®], an Immunotherapeutic


With Phase II Clinical Proof of Concept in Inflammatory Bowel Disease

- Compelling clinical improvement in 7 days
- Complete histological remission in 4 weeks
- Comprehensive IP Portfolio
- Excellent Safety Profile

PharmaVentures is seeking a licensee to complete the development and launch of Kappaproct

Efficacy in Phase II Study

- Single dose in steroid refractory patients: More than 30% clinical response and 10% in remission after one week. No clinical remission with placebo.
- Histological remission in 30% of patients four weeks after single dose. No improvement with placebo.
- Of all clinical responders in the treatment group, 55% showed concomitant histological remission. No histological improvement observed in any placebo responders.



Colectomy Elected Patient Rescue

In an ongoing rescue therapy program in Germany, 6 patients elected for radical surgery (colectomy) have received either single or repeat doses of Kappaproct. All patients, so far followed for up to 9 months, showed dramatic clinical improvement and none have undergone surgery.

No patients in the German program have experienced relapse. This is in line with pilot study results, which implies a disease modifying action of Kappaproct.

Safety

- Over 150 patients dosed to date
- No treatment related adverse events
- Comprehensive toxicology data

Product Technical Summary

- DIMS (DNA-based Immunomodulatory Sequence) compounds easily druggable
- Local application of the drug with negligible systemic uptake
- Multiple routes of administration applicable

Development Summary

- Pilot study reported 2002
- Phase II study reported 2005
- Proof of concept study – interim analysis
- Rescue therapy program – ongoing

Intellectual Property

- Extensive IP portfolio in all relevant jurisdictions providing protection for a range of DIMS based immunotherapeutic opportunities.
- Exclusive license from Johnson & Johnson, USA, on IP granted in 2002 providing protection for Kappaproct and other DIMS compounds in the US. Notice of allowance in EU.
- Additional IP for diagnostic tests for IBD and IBS

Additional Information

- InDex has several proprietary DIMS drugs targeting a range of diseases, including inflammation and cancer which affect millions of people around the world.
- Several multi-gene diagnostics have been developed including DiBiCol[®] to improve diagnosis of gastrointestinal diseases.

Market Information

- Over 3,000,000 IBD patients in USA & Europe
- Over 100,000 hospitalizations per year in the USA
- Up to every third IBD patient become resistant to or dependent on glucocorticosteroids
- Long standing IBD leads to colectomy in 30% of such patients
- Kappaproct rescue therapy would target over 30,000 colectomy patients

InDex Pharmaceuticals AB
InDex Pharmaceuticals AB discovers and develops DIMS drugs (DNA-based immunomodulatory sequence).

InDex innovations in immunotherapy offer:

- enhanced steroid treatment response in patients with chronic inflammation,
- enhanced antibody treatment response in patients with hematologic malignancy,
- new treatment alternatives in areas such as multiple sclerosis, airway inflammation and ischemic injury.

For more information:

Adrian Dawkes, Managing Consultant

PharmaVentures Ltd. | Magdalen Centre | Oxford Science Park | Oxford OX4 4GA | UK
adrian.dawkes@pharmaventures.com | +44 (0)7931 428 487